Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib. Issue 6 (25th November 2021)

• Record Type: Journal Article
• Authors: Buffet, Camille; Leboulleux, Sophie; Kraeber-Bodéré, Françoise; Bodet-Milin, Caroline; Cabanes, Laure; Dohan, Anthony; Leprince, Pascal; Schlumberger, Martin; Huillard, Olivier; Groussin, Lionel
• Is Part Of: European thyroid journal. Volume 10:Issue 6(2021)
• Page Start: 517
• Page End: 522
• Publication Date: 2021-11-25
• Subjects: Medullary thyroid cancers -- Cardiac metastasis -- Rearranged during transfection inhibitors -- Vandetanib -- Rearranged during transfection mutation; Thyroid gland -- Diseases -- Periodicals; Thyroid Diseases -- Periodicals; 612.44
• DOI: 10.1159/000517716
• Languages: English
• ISSNs: 2235-0640

Abstract

Abstract : Background: Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. There is a lack of long-term follow-up studies. Cases: We report 2 cases of cardiac metastasis from medullary thyroid cancer (MTC). Both patients presented limited metastatic disease apart from a cardiac metastasis. The initial diagnosis was challenging and was facilitated by functional imaging with an immuno-PET-CT using an anti-CEA bispecific antibody and a 68 Ga-labeled peptide. Both patients were treated with the multitarget kinase inhibitor vandetanib with prolonged stability. The first patient was alive at the last follow-up, 14 years after the diagnosis of cardiac metastasis. The second patient required surgical excision of the cardiac mass because of disease progression under vandetanib. Conclusion: These cases illustrate long-term survival and effectiveness of clinical management of 2 patients who developed cardiac metastases from MTC, in the current era of personalized medicine with targeted therapy.